Claims

[Claim 1.] Use of tandospirone or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for A composition for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for in Parkinson's disease, wherein the medicament is to be comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

[Claim 2.] The composition use of claim 1, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.

[Claim 3.] The composition use of claim 1 or claim 2, wherein the parenteral administration has sustainability or is to be sustainably administered.

[Claim 4.] The composition use of any one of claims 1 to 3, wherein the parenteral administration comprises transdermal administration.

[Claim 5.] The composition use of any one of claims 1 to 4, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).

[Claim 6.] Use of tandospirone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament A composition for treating, improving, or preventing motor complications associated with levodopa therapy forin Parkinson's disease, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein levodopa induced dyskinesia (PD-LID) is improved without resulting in a rebound symptom, and wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereofmedicament is to be transdermally administered.

[Claim 7.] The composition use of claim 6, wherein levodopa induced dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.

[Claim 8.] The composition use of claim 6 or claim 7, wherein the treatment, improvement, suppression of progression, or prevention of motor complications comprises improvement, suppression of progression, or prevention of- levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.

[Claim 9.] Use of tandospirone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament A composition for accomplishing improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, comprising tandospirone or

~~a pharmaceutically acceptable salt or prodrug thereof,~~ wherein the ~~tandospirone or a pharmaceutically acceptable salt or prodrug thereof~~medicament is to be parenterally administered.

~~[Claim~~ 10.~~]~~ The ~~composition~~ use of claim 9, wherein the improvement of levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.

~~[Claim~~ 11.~~]~~ The ~~composition~~ use of claim 9 or claim 10, wherein the improvement levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.

~~[Claim~~ 12.~~]~~ The ~~composition~~ use of any one of claims 9 to 11, wherein the ~~composition~~ medicament is a transdermally administ~~e~~rable~~ed~~ formulation.

~~[Claim~~ 13.~~]~~ The ~~composition~~ use of any one of claims 9 to 12, wherein the ~~composition~~ medicament is an adhesive formulation.

~~[Claim~~ 14.~~]~~ The ~~composition~~ use of ~~any one of~~ claim~~s~~ 12 or claim ~~9 to~~ 13, wherein the~~a~~ transdermally administerable~~ed~~ formulation is a tape/patch.

~~[Claim~~ 15.~~]~~ The ~~composition~~ use of any one of claims 9 to 14, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt ~~or prodrug~~ thereof is 0.1 to 100 mg per day as a free form of tandospirone.

~~[Claim~~ 16.~~]~~ The ~~composition~~ use of any one of claims 9 to 15, wherein an amount of drug penetration for the tandospirone or a pharmaceutically acceptable salt ~~or prodrug~~ thereof is 0.1 to 20 mg per day as a free form of tandospirone.

~~[Claim~~ 17.~~]~~ The ~~composition~~ use of any one of claims ~~9~~ 12 to 16, wherein the ~~composition is a transdermally administered formulation, and a~~ total applied area per dose of the transdermally administerable formulation of the medicament is 1 to 100 cm^2.

~~[Claim~~ 18.~~]~~ The ~~composition~~ use of any one of claims 9 to 17, wherein the medicament ~~tandospirone or a pharmaceutically acceptable salt or prodrug thereof~~ is to be administered such ~~so~~ that a human blood (plasma)~~/~~-tandospirone concentration ~~is~~ of 0.05 to 20 ng/mL is maintained for 12 hours or longer per day.

~~[Claim~~ 19.~~]~~ The ~~composition~~ use of any one of claims 9 to 18, wherein the ~~tandospirone or a pharmaceutically acceptable salt or prodrug thereof~~medicament is to be administered ~~so~~ such that a human blood (plasma)~~/~~-tandospirone concentration ~~is~~ of 0.05 to 20 ng/mL is maintained for 8 to 16 hours after administration of the ~~tandospirone or a pharmaceutically acceptable salt or prodrug thereof~~medicament.

~~[Claim~~ 20.~~]~~ The ~~composition~~ use of any one of claims 9 to 19, wherein the ~~tandospirone or a pharmaceutically acceptable salt or prodrug thereof~~medicament is an adjunct of levodopa.

[Claim 21.] The composition use of any one of claims 9 to 20, which is to be used with levodopa as the fixed-dose combination or concomitantly as separate formulations.

[Claim 22] A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising a combination of tandospirone or a pharmaceutically acceptable salt or prodrug thereof and (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

[Claim 23] A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered in combination with (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

[Claim 24] A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa is administered in combination with tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

[Claim 25]22. Use of A composition for improving the exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient with dyskinesia, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for improving the exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient with dyskinesia wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereofmedicament is to be parenterally administered.

[Claim 26]23. The medicament or compositionuse of any one of claims 1 to 225, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof in the medicament is a free form of tandospirone.